Levofloxacin coated tablets 500 mg. №7

Description

Levofloxacin №7 leave and form of release
Tablets – 1 tab .:

Active ingredient: levofloxacin hemihydrate – 512.46 mg (corresponds to the content of levofloxacin – 500 mg);
Excipients: lactose monohydrate – 145.5 mg, microcrystalline cellulose – 51.3 mg, hypromellose – 20 mg, crospovidone – 15.2 mg, magnesium stearate – 15.2 mg;
Shell composition: film coating – 22 mg (polyvinyl alcohol – 8.8 mg, titanium dioxide – 5.328 mg, macrogol – 4.444 mg, talc – 3.256 mg, charming red dye – 0.1496 mg, quinoline yellow dye – 0.0154 mg, indigo carmine – 0.0066 mg) …
5/10/50/100 pcs. – contour cell packaging (aluminum / PVC) / polymer cans, cardboard packs.

Levofloxacin №7 Description of the dosage form
Film-coated tablets of pink color, oval, biconvex, with a risk; the cross section shows two layers – from white with a yellowish tinge to light yellow.

Levofloxacin №7 pharmachologic effect
Levofloxacin is a synthetic broad-spectrum antibacterial drug from the group of fluoroquinolones, containing levofloxacin, the levorotatory isomer of ofloxacin, as an active substance. Levofloxacin blocks DNA gyrase, disrupts supercoiling and stitching of DNA breaks, inhibits DNA synthesis, and causes deep morphological changes in the cytoplasm, cell wall and membranes.

Levofloxacin is active against most strains of microorganisms both in vitro and in vivo.

Aerobic gram-positive microorganisms: Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus spp, Listeria monocytogenes, Staphylococcus coagulase-negative methi-S (I), Staphylococcus aureus methi-S, Staphyloccus spp. and G, Streptococcus agalactiae, Streptococcus pneumoniae peni I / S / R, Streptococcus pyogenes, Viridans streptococci peni-S / R.

Aerobic gram-negative microorganisms: Acinetobacter baumannil, Acinetobacter spp, Actinobacillus actinomycetemcomitans, Citrobacter freundii, Eikenella corrodens, Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter cloacae, Enterobacter cloacae, Enterobacter cloacae, Enterobacter cloacae, Enterobacter coli, Enterobacter cloacae, Enterobacter coli, Enterobacter cloacae, Spp. Haemophilus parainfluenzae, Helicobacter pylori, Klebsiella oxytoca, Klebsiella pneumoniae, Klebsiella spp, Moraxela catarrhalis (3 + / p-, Morganella morganii, Neisseria gonorrhoeae Pasurella Pasurella Pasurella Pasurella Pasurella conisseria meningisit mirabilis, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Providencia spp, Pseudomonas aeruginosa, Pseudomonas spp, Salmonella spp, Serratia marcescens, Serratia spp.

Anaerobic microorganisms: Bacteroides fragilis, Bifidobacterium spp, Clostridium perfringens, Fusobacterium spp, Peptostreptococcus, Propionibacterum spp, Veilonella spp.

Other microorganisms: Bartonella spp, Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Legionella pneumophila, Legionella spp, Mycobacterium spp, Mycobacterium leprae, Micobacterium tuberculosis, Mycoplasma hominis.

Levofloxacin №7 Pharmacokinetics
Levofloxacin is rapidly and almost completely absorbed after oral administration. Food intake has little effect on the rate and completeness of absorption. The bioavailability of 500 mg of levofloxacin after oral administration is almost 100%. After taking a single dose of 500 mg of levofloxacin, Cmax is 5.2-6.9 μg / ml, the time to reach Cmax is 1.3 hours, T1 / 2 is 6-8 hours.

The connection with plasma proteins is 30-40%. It penetrates well into organs and tissues: lungs, bronchial mucosa, phlegm, organs of the genitourinary system, bone tissue, cerebrospinal fluid, prostate gland, polymorphonuclear leukocytes, alveolar macrophages.